StemCell Therapy

Bronze Nazareth- Pictures (Stem Cells)
Bronze Nazareth Album: School For The Blindman (2011)

By: killAgram070

Follow this link:
Bronze Nazareth- Pictures (Stem Cells) - Video

Stem Cells Revolutions: TRAILER
RENT or BUY film here: http://www.stemcellrevolutions.com Featuring beautiful hand-drawn animations and interviews with leading stem cell scientists, STEM CE...

By: Scottish Documentary Institute

Read more:
Stem Cells Revolutions: TRAILER - Video

Iran Among Three Top Countries In Extracting Stem Cells From Primary Teeth
.

By: DaNi Islam

Read more here:
Iran Among Three Top Countries In Extracting Stem Cells From Primary Teeth - Video

23. Stem Cells
MIT 7.013 Introductory Biology, Spring 2011 View the complete course: http://ocw.mit.edu/7-013S11 Instructor: Hazel Sive Professor Sive discusses cell fate a...

By: MIT

Excerpt from:
23. Stem Cells - Video

From stem cells to a possible treatment for Graft-versus-host disease
Xellbiogene #39;s laboratories will test a new pathway for treating Graft-versus-host disease.

By: Xellbiogene

Read the rest here:
From stem cells to a possible treatment for Graft-versus-host disease - Video

HealthWACH - Banking baby #39;s stem cells
For the latest news weather and sports visit: http://www.wach.com Like WACH Fox on Facebook: http://www.facebook.com/wachfox Follow WACH Fox on Twitter: http...

By: WACH FOX

Originally posted here:
HealthWACH - Banking baby's stem cells - Video

Fat stem cells regenerate cartilage in osteoarthritis
http://www.stemcellsarthritistreatment.com http://www.arthritistreatmentcenter.com Dr. Bui Hong Thien Khanh, head of orthopedics at the Ho Chi Minh City Medi...

By: Nathan Wei

Excerpt from:
Fat stem cells regenerate cartilage in osteoarthritis - Video

PUBLIC RELEASE DATE:

14-Jan-2014

Contact: Michelle Quivey mquivey@isscr.org 224-592-5012 International Society for Stem Cell Research

CHICAGO The International Society for Stem Cell Research (ISSCR) has announced the following 2014 award recipients, who will be formally recognized at its 12th Annual Meeting in Vancouver, taking place June 18-21, 2014:

The McEwen Award for Innovation, supported by the McEwen Centre for Regenerative Medicine, recognizes original thinking and groundbreaking research pertaining to stem cells or regenerative medicine that opens new avenues of exploration toward the understanding or treatment of human disease or affliction. The winner receives $100,000 USD. Past winners include James Thomson, Rudolf Jaenisch, Kazutoshi Takahashi and Shinya Yamanaka.

Award recipient Surani is a world leader in the field of epigenetics and the development of the mammalian germ line. His work on early mammalian development led to his involvement in the discovery of genomic imprinting and ongoing contributions to understanding the mechanistic basis of imprinting. Most relevant to stem cell biology, is his work on the cellular and molecular specification of the mammalian germ cell lineage, which impacted the field's understanding of how the germ line is established and the molecular mechanisms responsible for reprogramming the epigenome in order to generate the totipotent state.

"The ISSCR is thrilled to announce the McEwen Award for Innovation, our most prestigious award, will be presented to Azim Surani," Janet Rossant, ISSCR president, said. "His pioneering research, which has changed the face of epigenetics and advanced the field of stem cell biology, is a rare and significant contribution from a single individual."

The ISSCR-BD Biosciences Outstanding Young Investigator Award recognizes exceptional achievements by an ISSCR member and investigator in the early part of their independent career in stem cell research. The winner receives a $7,500 USD personal award and an opportunity to present at the ISSCR Annual Meeting. Past winners include Marius Wernig, Cdric Blanpain, Robert Blelloch, Joanna Wysocka and Konrad Hochedlinger.

Award recipient Greco established a noninvasive method to directly visualize skin stem cell division in real time in living animals the first of its kind for imaging any stem cell. By combining this method with laser ablation and transgenic lineage tracing, she captured previously inaccessible key information on stem cell behavior during tissue maintenance and regeneration. She demonstrated that the niche location of stem cells dictates their fates, the niche is required for tissue maintenance, and that a -catenin-mediated extrinsic mechanism regulates stem cell activation.

"The ISSCR is looking forward to presenting our Outstanding Young Investigator Award to Valentina Greco," Rossant said. "Her enthusiastic nomination by over a dozen leaders in the field of stem cell research demonstrates the significance of her early-career contributions to stem cell biology and regenerative medicine."

Follow this link:
The International Society for Stem Cell Research announces its 2014 award recipients

Published:Tuesday, January 14, 2014

Updated:Tuesday, January 14, 2014 18:01

A new tool that could help facilitate future stem cell therapy has recently been identified by a UVM professor and his colleagues, according to UVMs College of Medicine.

The development of this tool could potentially help more than 700,000 Americans who suffer a heart attack each year.

Because stem cells have the potential to develop into a variety of cell types in the body, they may offer a renewable source of replacement cells to treat diseases, conditions and disabilities, and even regenerate damaged tissue and organs.

However, the field of regenerative medicine has struggled to successfully graft cells from culture back into injured tissue.

UVM Associate Professor of Medicine Jeffrey Spees, Ph.D., collaborated with the Center for Gene Therapy at Tulane University. His research team recently set out to develop ways to enhance graft success.

Dr. Spees and his team focused on a type of bone marrow-derived progenitor cell or biological cell that forms stromal cells or connective tissue cells.

They found that the medium contained Connective Tissue Growth Factor (CTGF) and the hormone insulin, and together, they have a synergistic effect, Spees said to UVMs College of Medicine.

The group found that the protective ligands resulted in improved graft success, breaking the record for engraftment.

Link:
New tool assists stem cell therapy

Art of Science: Montage of Stem Cells by Peter Tonge
A montage of stem cells called "All for One - One for All" by Peter Tonge.

By: Mount Sinai Hospital

Read more:
Art of Science: Montage of Stem Cells by Peter Tonge - Video

Age Reversal Study - Testimony of Caleb during his 7th injection
http://a1stemcells.com/anti-aging-2 testimony of Caleb, 36yo, recorded during his 7th injection. It changed Caleb #39;s life. Stem cell rejuvenation program in M...

By: Edith Stem Cells

Read more here:
Age Reversal Study - Testimony of Caleb during his 7th injection - Video

ST. LOUIS -

Sickle cell is a serious disease that causes pain, anemia, infection, organ damage and even stroke. Its the most common inherited blood disorder in the United States.

The good news is bone marrow transplants can be a cure. The bad news is not every patient has a matching donor. Now, researchers are looking at a new way to offer more patients transplants.

Madisyn Travis is like any other 9-year-old, but theres something that sets Madisyn apart. She has sickle cell, an inherited red blood cell disease.

"It makes me feel bad, and sometimes I have to go to the hospital," Madisyn said.

"It's really hard to see her life interrupted," said Denise Travis, Madisyn's mom.

Soon, however, Madisyn will get a bone marrow transplant to cure her disease. Her little brother or sister are both matches, and one will be the donor.

Madisyn is one of the lucky ones. Only 14 percent of patients have a matching sibling.

"Ten years ago, we'd just tell them, 'Sorry, you have no family member. We cant transplant you,'" said Dr. Shalini Shenoy, professor of pediatrics and medical director, pediatric stem cell transplant program, Washington University School of Medicine, St. Louis Children's Hospital.

Shenoy is studying a new option for patients without related donors. Stem cells from a baby's umbilical cord can be infused in the arm. They travel to the bone marrow, settle there and make new cells.

See the article here:
Health Beat: Stem cells to cure sickle cell

14 months after Stem Cell Therapy by Dr Harry Adelson for arthritis of the knee
Nona discusses her outcome 14 months after Stem Cell Therapy by Dr Harry Adelson for arthritis of the knee http://www.docereclinics.com.

By: Harry Adelson

Go here to see the original:
14 months after Stem Cell Therapy by Dr Harry Adelson for arthritis of the knee - Video

PUBLIC RELEASE DATE:

12-Jan-2014

Contact: Jessica Studeny jessica.studeny@case.edu 216-368-4692 Case Western Reserve University

Geneticists from Ohio, California and Japan joined forces in a quest to correct a faulty chromosome through cellular reprogramming. Their study, published online today in Nature, used stem cells to correct a defective "ring chromosome" with a normal chromosome. Such therapy has the promise to correct chromosome abnormalities that give rise to birth defects, mental disabilities and growth limitations.

"In the future, it may be possible to use this approach to take cells from a patient that has a defective chromosome with multiple missing or duplicated genes and rescue those cells by removing the defective chromosome and replacing it with a normal chromosome," said senior author Anthony Wynshaw-Boris, MD, PhD, James H. Jewell MD '34 Professor of Genetics and chair of Case Western Reserve School of Medicine Department of Genetics and Genome Sciences and University Hospitals Case Medical Center.

Wynshaw-Boris led this research while a professor in pediatrics, the Institute for Human Genetics and the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UC, San Francisco (UCSF) before joining the faculty at Case Western Reserve in June 2013.

Individuals with ring chromosomes may display a variety of birth defects, but nearly all persons with ring chromosomes at least display short stature due to problems with cell division. A normal chromosome is linear, with its ends protected, but with ring chromosomes, the two ends of the chromosome fuse together, forming a circle. This fusion can be associated with large terminal deletions, a process where portions of the chromosome or DNA sequences are missing. These deletions can result in disabling genetic disorders if the genes in the deletion are necessary for normal cellular functions.

The prospect for effective counter measures has evaded scientistsuntil now. The international research team discovered the potential for substituting the malfunctioning ring chromosome with an appropriately functioning one during reprogramming of patient cells into induced pluripotent stem cells (iPSCs). iPSC reprogramming is a technique that was developed by Shinya Yamanaka, MD, PhD, a co-corresponding author on the Nature paper. Yamanaka is a senior investigator at the UCSF-affiliated Gladstone Institutes, a professor of anatomy at UCSF, and the director of the Center for iPS Cell Research and Application (CiRA) at the Institute for Integrated Cell-Material Sciences (iCeMS) in Kyoto University. He won the Nobel Prize in Medicine in 2012 for developing the reprogramming technique.

Marina Bershteyn, PhD, a postdoctoral fellow in the Wynshaw-Boris lab at UCSF, along with Yohei Hayashi, PhD, a postdoctoral fellow in the Yamanaka lab at the Gladstone Institutes, reprogrammed skin cells from three patients with abnormal brain development due to a rare disorder called Miller Dieker Syndrome, which results from large terminal deletions in one arm of chromosome 17. One patient had a ring chromosome 17 with the deletion and the other two patients had large terminal deletions in one of their chromosome 17, but not a ring. Additionally, each of these patients had one normal chromosome 17.

The researchers observed that, after reprogramming, the ring chromosome 17 that had the deletion vanished entirely and was replaced by a duplicated copy of the normal chromosome 17. However, the terminal deletions in the other two patients remained after reprogramming. To make sure this phenomenon was not unique to ring chromosome 17, they reprogrammed cells from two different patients that each had ring chromosomes 13. These reprogrammed cells also lost the ring chromosome, and contained a duplicated copy of the normal chromosome 13.

Here is the original post:
Nature study discovers chromosome therapy to correct a severe chromosome defect

one year after stem cell therapy by Dr Harry Adelson for an arthritic ankle
Jim discusses his outcome one year after stem cell therapy by Dr Harry Adelson for an arthritic ankle http://www.docereclinics.com.

By: Harry Adelson

Read the rest here:
one year after stem cell therapy by Dr Harry Adelson for an arthritic ankle - Video

Stem Cells basic story
Stem Cells, Nutrition, Health and Fitness, Super Human, Humans, medication.

By: Moez Fawaz

Read more here:
Stem Cells basic story - Video

Regenerative Medicine at Florida Orthopaedic Institute
Regenerative medicine is one of the most exciting new treatment options in orthopedics. Learn more about stem cell therapy, and other regenerative procedures...

By: flortho

Go here to see the original:
Regenerative Medicine at Florida Orthopaedic Institute - Video

Stem Cell therapy for Cartilage Regeneration in Orthopaedic Surgery
Prof. A A Shetty and Prof. Seok Jung Kim, founders of Shetty - Kim Research Foundation were here at MediCiti to perform 5 stem cell therapy surgeries on 31st...

By: Mediciti Hospitals

See original here:
Stem Cell therapy for Cartilage Regeneration in Orthopaedic Surgery - Video

VAIL The Vail Symposium hosts Dr. Scott Brandt, Dr. Kristin Comella and Dr. Stan Jones who will lead an interactive discussion on the history, evolution, practical applications and clinical results around stem cell treatments Friday evening in Vail.

The program is part of the Symposiums ongoing Living at Your Peak series, which is dedicated to exploring new breakthroughs in medicine and helping people live healthier, more active lives.

This program fits perfectly with our Living at Your Peak series, said Tracey Flower, the Symposiums executive director. There is a lot surrounding this topic, and has been for quite some time. With recent research in a changing medical industry, it is a great topic to discuss.

An example of breakthroughs in stem cell therapy comes in the form of the record-shattering Broncos quarterback, Peyton Manning. After failed surgeries, Manning traveled to Germany to undergo stem cell treatment on his cervical spine. At 37, Manning is playing his best football.

During this educational program, panelists will discuss the evolution of the stem cell field, explain current procedures, present research and clinical findings, and talk about the potential for stem cell applications in the future.

Join the Vail Symposium at 5 p.m. Friday at the Antlers Hotel in Vail for this event, titled: Stem Cells: The Future of Medicine is Now. Space is limited; reserve your tickets at http://www.vailsymposium.org/calendar or call the Vail Symposium at 970-476-0954.

More about the panelists

Dr. Scott Brandt: Brandt, the medical director of ThriveMD in Edwards, specializes in regenerative and restorative medicine. Brandt completed his undergraduate studies at the University of Michigan at Ann Arbor, and attended medical school at Bowman Gray School of Medicine, Wake Forest University in North Carolina. He then completed his anesthesiology residency training and internship at the University of Illinois and Michael Reese Hospitals in Chicago. As a resident in anesthesiology, Brandt specialized in interventional pain management. Since 1997, this focus has kept him on the leading edge of medical innovations that provide longer lasting solutions for acute and chronic pain. The advancement of stem cell therapy, coupled with Brandts expertise in image-guided injections, has made joint rejuvenation an important part of his practice.

Dr. Kristin Comella: In 2013, Comella was named as one of the 25 most influential people in the stem cell field. She has more than 14 years of experience in regenerative medicine, training and education, research, product development and has served in a number of senior management positions with stem cell related companies. Comella has more than 12 years of cell culturing experience including building and managing the stem cell laboratory at Tulane Universitys Center for Gene Therapy. She has also developed stem cell therapies for osteoarthritis at Osiris Therapeutics. Comella has been a member of the Bioheart senior management team since 2004 and is currently serving as its chief scientific officer.

Dr. Stan Jones: Widely known for performing a ground-breaking stem cell infusion on Governor Rick Perry during a spinal surgery in 2011, Jones is a surgeon and stem cell expert. He received his bachelors degree from Texas Tech in Lubbock before earning his medical degree from the University of Texas Southwestern Medical School in Dallas. Jones continued his medical training at the University of Utah Medical School in Salt Lake City and a residency at the University of Texas Medical School at Houston. Jones was awarded a fellowship to study the lower back at Wellseley Hospital in Toronto, Canada. In addition, he served in the U.S. Army Medical Corp as a Captain. He is licensed to practice in the state of Texas and is certified by the American Board of Orthopedic Surgery.

See the original post here:
Learn about stem cell therapy and application at Vail event

PUBLIC RELEASE DATE:

8-Jan-2014

Contact: David McKeon DMckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation

NEW YORK, NY (January 8, 2014) Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute in collaboration with scientists at the Icahn School of Medicine at Mount Sinai (ISMMS) successfully generated a stem cell model of familial Alzheimer's disease (FAD). Using this stem cell model, researchers identified fourteen genes that may be implicated in the disease and one gene in particular that shows the importance that inflammation may play in the brain of Alzheimer's patients.

In this study, published today in PLOS ONE, the team of scientists produced stem cells and neural precursor cells (NPCs), representing early neural progenitor cells that build the brain, from patients with severe early-onset AD with mutations in the Presenilin 1 (PSEN1) gene. These NPCs had elevated Abeta42/Abeta40 ratios, indicating elevation of the form of amyloid found in the brains of Alzheimer's patients. These levels were greater than those in adult cells that did not have the PSEN1mutation. This elevated ratio showed that these NPCs grown in the petri dish were accurately reflecting the cells in the brains of FAD patients.

"Our ability to accurately recapitulate the disease in the petri dish is an important advance for this disease. These genes provide us with new targets to help elucidate the cause of sporadic forms of the disease as well provide targets for the discovery of new drugs," said Susan L. Solomon, Chief Executive Officer of The New York Stem Cell Foundation.

"The gene expression profile from Noggle's familial Alzheimer's stem cells points to inflammation which is especially exciting because we would not usually associate inflammation with this particular Alzheimer's gene. The greatest breakthroughs come with 'unknown unknowns', that is, things that we don't know now and that we would never discover through standard logic," said Sam Gandy, MD, PhD, Professor of Neurology and Psychiatry and Director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai and a co-author on the study. Gandy is also Associate Director of the NIH-Designated Mount Sinai Alzheimer's Disease Research Center.

The researchers generated induced pluripotent stem (iPS) cells from affected and unaffected individuals from two families carrying PSEN1 mutations. After thorough characterization of the NPCs through gene expression profiling and other methods, they identified fourteen genes that behaved differently in PSEN1 NPCs relative to NPCs from individuals without the mutation. Five of these targets also showed differential expression in late onset Alzheimer's disease patients' brains. Therefore, in the PSEN1 iPS cell model, the researchers reconstituted an essential feature in the molecular development of familial Alzheimer's disease.

Although the majority of Alzheimer's disease cases are late onset and likely result from a mixture of genetic predisposition and environmental factors, there are genetic forms of the disease that affect patients at much earlier ages. PSEN1 mutations cause the most common form of inherited familial Alzheimer's disease and are one hundred percent penetrant, resulting in all individuals with this mutation getting the disease.

The identification of genes that behaved differently in patients with the mutation provides new targets to further study and better understand their effects on the development of Alzheimer's disease. One of these genes, NLRP2, is traditionally thought of as an inflammatory gene.

Excerpt from:
Stem cell research identifies new gene targets in patients with Alzheimer's disease